ArticleCancer biology & therapy2025
YTHDF2 enhances proliferation and metastasis of nasopharyngeal carcinoma by mediating m6A modification in destabilizing FOXO1 mRNA.
Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAberrant N6-methyladenosine (m6A) modification is linked to cancer development and progression. However, the role of YTH N6-methyladenosine RNA binding protein F2 (YTHDF2), an m6A 'reader protein', in nasopharyngeal carcinoma (NPC) is poorly understood. This study aimed to clarify the role and mechanism of YTHDF2 in NPC development.
methodsBioinformatics analysis was performed to identify the differential expression, prognostic value, and enriched pathways of YTHDF2 in patients with NPC. Quantitative PCR, western blotting, and immunohistochemistry were used to detect mRNA and protein expression. Biological function of YTHDF2 was investigated using
resultsYTHDF2 mRNA and protein levels were significantly increased in the NPC tissues and cell lines. Higher expression of YTHDF2 was associated with a poorer prognosis. Overexpressing YTHDF2 enhanced the NPC cell proliferation, migration, and invasion. Conversely, YTHDF2 knockdown inhibited these phenomena. Gene set enrichment analysis revealed that FOXO1-related signaling pathways were enriched in the YTHDF2-activated group. Mechanistically, YTHDF2 overexpression inhibited FOXO1 expression in NPC cells. RIP-seq, RIP-qPCR, and MeRIP-seq assays confirmed that YTHDF2 was bound to FOXO1 mRNA, reducing its stability and accelerated degradation.
conclusionYTHDF2 potentially functions as an oncogene in NPC by binding to the m6A site of FOXO1, reducing its expression, thereby promoting malignant behavior. It may also be a viable biomarker and therapeutic target for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.